News Commentary | January 2, 2019
Teva recently received marketing approval from the U.S. FDA for its ProAir Digihaler. The device is indicated for the treatment and prevention of obstructive airway diseases like asthma. A key challenge today for physicians is knowing if their patients are using their inhaled medication as intended... Not part of subscription
Case Study | May 10, 2019
Diabetes is one of the most expensive chronic diseases to manage today. In India, diabetes is officially the fastest‑growing disease. There are more than 70 million Type 2 diabetics, and the number is expected to double by 2025. Interestingly, robust clinical intervention plans exists to manage ... Not part of subscription
News Commentary | July 19, 2018
The data is drawn from the first year of an ongoing pilot that started in 2016 and has shown a 27% lower rate of preventable hospital admissions over patients relying on multiple daily injections of insulin. Medtronic's insulin pump delivers basal insulin every five minutes based on real‑time sensor... Not part of subscription
by Nardev Ramanathan
Roche and Wellthy Therapeutics partnered last year to test self-management practices for Type 2 diabetes using Roche's Accu-Chek and Wellthy's digital therapeutic (DTx). The study found that those with the highest engagement with Wellthy's DTx saw the largest reduction in blood sugar levels. The results were especially encouraging because they were found in a real-world setting, as opposed to a clinical trial setting. Roche has moved quickly to build a digital diabetes management ecosystem in a resource-constrained and low-health-literacy market. This is a great example of a foreign multinational tailoring its approach to fit local market needs and partnering with a local startup that's well-placed to understand local consumer behavior.
For the original news article, click here .